David Hallett
Chief Scientific OfficerDr. David Hallett, also known as Dave, Ph.D. is the Chief Operations Officer of Exscientia Limited since January 2020. He served as Chief Operating Officer at Exscientia plc since June 2022 until 2022 and served as its Chief Operations Officer since January 2020 until June 2022. He was Chief Scientific Officer of Exscientia plc since February 2023 & served as it's Interim Chief Executive Officer until November 20, 2024 and served as its Interim Principal Executive Officer and Executive Director. He has experience in drug discovery and alliance management. Prior to joining, he served as Executive Vice President of Chemistry and Executive Vice President of Alliance Management at Evotec from September 2005 to December 2019. He trained as a medicinal chemist and served as a Research Fellow at Merck & Co. Inc. Dr. Hallett is Chief Scientific Officer of Recursion Pharmaceuticals, Inc. from November 20, 2024. He holds a B.A. from the University of Cambridge in Natural Sciences, a Ph.D. from the University of Manchester in Synthetic Organic Chemistry and was a post-doctoral fellow in Synthetic Organic Chemistry at the University of Texas Austin.
Positions
- Company NameRecursion Pharmaceuticals, Inc.Stock CodeRXRXPositionChief Scientific OfficerColleagues
- NKNajat KhanCEO, President & Director
- FHFred HassanChair of the Board
- BRBen R. TaylorCFO & President of Recursion UK
- BMBenjamin MabeyChief Technology Officer
- NHNathan HatfieldChief Legal Officer & Corporate Secretary
- ZDZavain DarIndependent Director
- RMRobert M. HershbergIndependent Director
- JPJoseph P. MiletichChairman of Therapeutics Advisory Board
